NO151587B - Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylamino-imidazolin-derivater - Google Patents
Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylamino-imidazolin-derivater Download PDFInfo
- Publication number
- NO151587B NO151587B NO803748A NO803748A NO151587B NO 151587 B NO151587 B NO 151587B NO 803748 A NO803748 A NO 803748A NO 803748 A NO803748 A NO 803748A NO 151587 B NO151587 B NO 151587B
- Authority
- NO
- Norway
- Prior art keywords
- acid
- phenylamino
- general formula
- chlorine
- radical
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 5
- 238000000034 method Methods 0.000 title claims description 3
- 230000001225 therapeutic effect Effects 0.000 title description 2
- SACAEVOKRBNXPN-UHFFFAOYSA-N n-phenyl-4,5-dihydroimidazol-1-amine Chemical class C1=NCCN1NC1=CC=CC=C1 SACAEVOKRBNXPN-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 8
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000460 chlorine Substances 0.000 claims abstract description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims abstract 2
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 2
- 239000011737 fluorine Substances 0.000 claims abstract 2
- -1 alkyl radical Chemical class 0.000 claims description 7
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- JCOPITWIWLFFPC-UHFFFAOYSA-N n-phenyl-4,5-dihydro-1h-imidazol-2-amine Chemical class N1CCN=C1NC1=CC=CC=C1 JCOPITWIWLFFPC-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 230000000059 bradycardiac effect Effects 0.000 abstract description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- YIUIVFFUEVPRIU-UHFFFAOYSA-N 8-chlorotheophylline Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21 YIUIVFFUEVPRIU-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- WGVPTCYKVRRBQC-UHFFFAOYSA-N n-(2-bromo-6-fluorophenyl)-n-(4,5-dihydro-1h-imidazol-2-yl)hydroxylamine;hydrochloride Chemical compound Cl.FC=1C=CC=C(Br)C=1N(O)C1=NCCN1 WGVPTCYKVRRBQC-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/52—Nitrogen atoms not forming part of a nitro radical with hetero atoms directly attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Description
Denne oppfinnelse angår en fremgangsmåte for fremstilling av nye substituerte 2-fenylamino-imidazolin-(2)-derivater med den generelle formel I
og deres fysiologisk forlikelige syreaddisjonssalter med verdi-fulle terapeutiske egenskaper.
I formel I betyr
og 1*2, som kan være like eller forskjellige, et fluor-,
klor- eller bromatom, eller en trifluormetylgruppe, og R- en alkylrest med opptil 4 C-atomer, en alkenylrest med opptil 4 C-atomer, en cyklopropylmetyl-, benzyl- eller tieny1-2-metyl-rest,, idet R^ og R2 ikke samtidig kan bety et kloratom når R-j betyr en alkylrest med l-4karbonatomer eller en benzylrest.
Forbindelsene med formel I fremstilles ved omsetning av
et 2-fenylamino-imidazolin-(2) med den generelle formel II
hvor R^ og R,, har de ovenfor angitte betydninger, med et halogenid med den generelle formel III
hvor Hal betyr et klor-, brom- eller jodatom, og R^ har de ovenfor angitte betydninger.
Omsetningen utføres fortrinnsvis i nærvær av et polart
eller upolart oppløsningsmiddel ved romtemperatur, idet hensiktsmessig natriumsaltene av forbindelsene med formel II omsettes med halogenidene med formel III. De spesielle reaksjons-
betingelser er i sterk grad avhengig av reaktiviteten av reaksjonskomponentene. Ved alkyleringen anbefales det å anvende halogenidet med den generelle formel III i overskudd og utføre omsetningen i nærvær av et syrebindende middel.
Utgangsforbindelsene med formel II er kjent fra litteraturen (se tysk off.skrift 2.457.979). Forbindelser med formel III kan fremstilles ved halogenering av de tilsvarende alkoholer.
De nye 2-fenylamino-imidazolin-(2)-derivater med den generelle formel I kan på vanlig måte overføres til sine fysiologisk forlikelige syreaddisjonssalter. Syrer som er egnet for saltdannelse er f.eks. saltsyre, bromhydrogensyre, jod-hydrogensyre, fluorhydrogensyre, svovelsyre, fosforsyre, salpetersyre, eddiksyre, propionsyre, smørsyre, kapronsyre, valeriansyre, oksalsyre, malonsyre, ravsyre, maleinsyre, fumarsyre, melkesyre, vinsyre, sitronsyre, eplesyre, benzoesyre, p-hydroksybenzoesyre, p-aminobenzoesyre, ftalsyre, kanelsyre, salicylsyre, askorbinsyre, metansulfonsyre, 8-klorteofyllin og lignende.
De nye forbindelser med den generelle formel I og deres syreaddisjonssalter har en sterk bradykard virkning og er derfor egnet til behandling av coronarlidelser. Innvirkningen på hjertefrekvensen undersøkes på kaniner og på spinalbedøvede rotter, samt på intakte, narkotiserte rotter. Doseringen ligger ved 0,1 til 80 mg, fortrinnsvis 1 til 30 mg.
Forbindelsene med formel I og deres syreaddisjonssalter kan også anvendes sammen med andre typer aktive stoffer. Egnede galeniske tilberedelsesformer er f.eks. tabletter, kapsler, stikkpiller, oppløsninger eller pulvere, og. for fremstilling av slike preparater kan man anvende de vanlig anvendte galeniske hjelpestoffer, bæremidler, sprengmidler eller smøremidler eller stoffer som medfører en depotvir-kning.
De følgende eksempler skal tjene til å illustrere oppfinnelsen ytterligere.
Eksempel 1
2-[ N- allyloksy- N-( 2- brom- 6- fluorfenyl) amino]- 2- imidazolin
5 g (0,016 mol) 2-[N-(2-brom-6-fluorfenyl)-N-(hydroksy)-amino]-2-imidazolin-hydroklorid oppløses sammen med 0,7 g natrium i 75 cm 3 absolutt etanol, og til oppløsningen settes 1,6 ml (ca. 115%) allylbromid.
Reaksjonsblandingen omrøres derefter i 1 time ved romtemperatur. Efter inndampning oppløser man det gjenværende residuum i fortynnet saltsyre (ca. IN) og ekstraherer den saltsure oppløsning (eterekstraktene kastes). Ved stigende pH-verdier (trinnvis alkalisering med 2N natronlut) foretas fraksjonert ekstraksjon med eter (også disse ekstrakter kastes).
Derefter alkaliseres med 5N NaOH, hvorved det utfelles meget rent 2-[N-allyloksy-N-(2-brom-6-fluorfenyl)amino]-2-imidazolin som et hvitt, amorft stoff. Utbytte efter avsugning, vasking med vann og tørring: 2,95 g (svarende til 58,3% av det teoretiske).
Smeltepunkt: 141°C.
På analog måte ble de følgende i tabellen angitte forbindelser syntetisert.
Farmakologiske forsøksresultater
Noen av forbindelsene fremstilt ifølge oppfinnelsen ble undersøkt på kaniner med hensyn til sin hjertefrekvens-senkende virkning, hvorved man oppnådde følgende resultater:
Claims (1)
- Analogifremgangsmåte for fremstilling av terapeutisk aktive, substituerte2-fenylamino-imidazolin-derivater med den generelle formelhvor og R2» som kan være like eller forskjellige, betyr et fluor-., klor- eller bromatom eller en trif luorme tyl gruppe, og R^ betyr en alkylrest med opptil 4 C-atomer, en alkenylrest med opptil 4 C-atomer, en cyklopropylmetyl-, benzyl- eller tienyl-2-metylrest, idet R-^ og R2 ikke samtidig kan bety et kloratom når R^ betyr en alkylrest med 1-4 karbonatomer eller en benzylrest,og syreaddisjonssalter derav, karakterisert ved at 2-fenylamino-imidazolin-(2) med den generelle formel IIhvor og R2 har de ovenfor angitte betydninger, eller et natriumsalt derav, omsettes med et halogenid med den generelle formel IIIhvor Hal betyr et klor-, brom- eller jodatom, og R^ har de ovenfor angitte betydninger,og eventuelt overføres det erholdte produkt i et syreaddisjonssalt.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19792950345 DE2950345A1 (de) | 1979-12-14 | 1979-12-14 | Neue substituierte 2-phenylaminoimidazoline-(2), deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO803748L NO803748L (no) | 1981-06-15 |
| NO151587B true NO151587B (no) | 1985-01-21 |
| NO151587C NO151587C (no) | 1985-05-08 |
Family
ID=6088485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO803748A NO151587C (no) | 1979-12-14 | 1980-12-12 | Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylamino-imidazolin-derivater |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US4327106A (no) |
| EP (1) | EP0030620B1 (no) |
| JP (1) | JPS5692873A (no) |
| AT (1) | ATE7913T1 (no) |
| AU (1) | AU535927B2 (no) |
| DE (2) | DE2950345A1 (no) |
| DK (1) | DK531080A (no) |
| ES (1) | ES8202544A1 (no) |
| FI (1) | FI73414C (no) |
| IE (1) | IE51062B1 (no) |
| IL (1) | IL61695A (no) |
| NO (1) | NO151587C (no) |
| ZA (1) | ZA807790B (no) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2499991A1 (fr) * | 1981-02-19 | 1982-08-20 | Sandoz Sa | Nouveaux 2,1,3-benzothiadiazoles et 2,1,3-benzoxadiazoles, leur preparation et leur application comme medicaments |
| US4461904A (en) * | 1981-11-20 | 1984-07-24 | Alcon Laboratories, Inc. | 2-(Trisubstituted phenylimino)-imidazolines |
| US8328017B2 (en) | 2006-04-11 | 2012-12-11 | Poppack, Llc | User inflated breachable container, and method |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2016290A1 (de) * | 1970-04-06 | 1971-11-04 | C H Boehrmger Sohn, 6507 Ingel heim | Substituierte N Hydroxylakyl 2 arylamine) imidazoline (2) und Verfahren zu deren Herstellung |
| DE2457979A1 (de) * | 1974-12-07 | 1976-06-16 | Beiersdorf Ag | 2-n-aryl-hydroxyamino-imidazoline-(2) und verfahren zu deren herstellung |
| DE2830278A1 (de) * | 1978-07-10 | 1980-01-31 | Boehringer Sohn Ingelheim | Neue substituierte 2-phenylamino-imidazoline-(2), deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben |
| DE2831671A1 (de) * | 1978-07-19 | 1980-02-07 | Boehringer Sohn Ingelheim | Neue substituierte 2-phenylamino-imidazoline-(2), deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben |
| DE2855306A1 (de) * | 1978-12-21 | 1980-07-10 | Boehringer Sohn Ingelheim | Mittel zur senkung der herzfrequenz |
-
1979
- 1979-12-14 DE DE19792950345 patent/DE2950345A1/de not_active Withdrawn
-
1980
- 1980-11-10 AT AT80106918T patent/ATE7913T1/de not_active IP Right Cessation
- 1980-11-10 DE DE8080106918T patent/DE3068245D1/de not_active Expired
- 1980-11-10 EP EP80106918A patent/EP0030620B1/de not_active Expired
- 1980-12-10 US US06/215,105 patent/US4327106A/en not_active Expired - Lifetime
- 1980-12-11 JP JP17520580A patent/JPS5692873A/ja active Pending
- 1980-12-12 AU AU65371/80A patent/AU535927B2/en not_active Ceased
- 1980-12-12 NO NO803748A patent/NO151587C/no unknown
- 1980-12-12 FI FI803887A patent/FI73414C/fi not_active IP Right Cessation
- 1980-12-12 ZA ZA00807790A patent/ZA807790B/xx unknown
- 1980-12-12 ES ES497664A patent/ES8202544A1/es not_active Expired
- 1980-12-12 IL IL61695A patent/IL61695A/xx unknown
- 1980-12-12 DK DK531080A patent/DK531080A/da not_active Application Discontinuation
- 1980-12-12 IE IE2602/80A patent/IE51062B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO151587C (no) | 1985-05-08 |
| EP0030620B1 (de) | 1984-06-13 |
| DE3068245D1 (en) | 1984-07-19 |
| DK531080A (da) | 1981-06-15 |
| FI803887L (fi) | 1981-06-15 |
| ZA807790B (en) | 1982-07-28 |
| IE51062B1 (en) | 1986-09-17 |
| DE2950345A1 (de) | 1981-07-02 |
| ATE7913T1 (de) | 1984-06-15 |
| FI73414C (fi) | 1987-10-09 |
| JPS5692873A (en) | 1981-07-27 |
| AU6537180A (en) | 1981-06-18 |
| EP0030620A2 (de) | 1981-06-24 |
| EP0030620A3 (en) | 1981-09-02 |
| ES497664A0 (es) | 1982-02-01 |
| IL61695A0 (en) | 1981-01-30 |
| ES8202544A1 (es) | 1982-02-01 |
| AU535927B2 (en) | 1984-04-12 |
| IL61695A (en) | 1984-10-31 |
| FI73414B (fi) | 1987-06-30 |
| NO803748L (no) | 1981-06-15 |
| IE802602L (en) | 1981-06-14 |
| US4327106A (en) | 1982-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE68928992T2 (de) | Chinolin-Derivate als Leukotrien-D4-Antagonisten, diese enthaltende Zusammensetzungen und Verfahren zu deren Herstellung | |
| AU2014239995B2 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| EP0307303B1 (fr) | [(Pyrimidinyl-2)-aminoalkyl]-1 pipéridines, leur préparation et leur application en thérapeutique | |
| HUT50335A (en) | Process for producing saturated heterocyclic carboxamide derivatives and pharmaceutical compositions comprising the compounds | |
| PT92041B (pt) | Processo para a preparacao de derivados de acido o-(3-amino-2-hidroxipropil)-hidroximico e de composicoes farmaceuticas que os contem | |
| HU188353B (en) | Process for producing new xanthine derivatives | |
| RU2162081C2 (ru) | Способ получения ламотриджина и промежуточное соединение, используемое при его получении | |
| US20040259860A1 (en) | Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method | |
| CS207774B2 (en) | Method of making the new substituted 2-phenyliminoimidazolines | |
| DE1957722A1 (de) | Neue substituierte N-Aminoalkyl-arylaminoimidazoline-(2) und Verfahren zu deren Herstellung | |
| NO151587B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylamino-imidazolin-derivater | |
| NO145275B (no) | Analogifremgangsmaate for fremstilling av imidazolinderivater og deres syreaddisjonssalter | |
| DE1804306A1 (de) | Verfahren zur Herstellung von neuen 2-Cycloalkyl-heteroaryl-Verbindungen | |
| NO150436B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-fenylamino-imidazolin-derivater | |
| IE921319A1 (en) | 2-aminopyrimidine-4-carboxamide derivatives, their¹preparation and their application in therapy | |
| EP2313384B1 (fr) | Phenyl-alkyl piperazines ayant une activite modulatrice du tnf | |
| NO150435B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylamino-imidazolin-derivater | |
| DE60000500T2 (de) | Substituierte n-(piperidin-4-yl)-4h-3,1-benzo(thia/oxa)zin-2-amine, ihre herstellung und therapeutische verwendung | |
| NO151412B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylamino-imidazolin-derivater | |
| DE69624459T2 (de) | Kondensierte indan-derivate und ihre salze | |
| DE69707080T2 (de) | Pyrrolidinonderivate und ihre Verwendung als antipsychotische Arzneimittel | |
| EP0007007B1 (de) | 2-(N-(2'-Chlor-4'-methyl-thienyl-3')-N-(cyclopropylmethyl)-amino)-imidazolin-(2), dessen Säureadditionssalze, dieses enthaltende Arzneimittel und Verfahren zu seiner Herstellung | |
| NO128570B (no) | ||
| NO792406L (no) | Analogifremgangsmaate for fremstilling av substituerte 2-fenylamino-imidazoliner | |
| EP4461727A1 (en) | Crystal form of 7-azaspiro[4,5]decane-6,10-dione compound and preparation method therefor |